US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,203.90

-21.0316-1.72%

Number of Gainers:4

Number of Losers:2

Number of Flat:- -

PE:- -

High:1,211.82

Open:1,200.66

Low:1,195.12

Close:1,224.93

Loading ...

MannKind Q4 Net Income USD 7.422 Million

THOMSON REUTERS

MannKind Q4 Basic EPS USD 0.03

THOMSON REUTERS

MannKind Q4 Pretax Profit USD 8.445 Million

THOMSON REUTERS

Teva, Medincell announce FDA acceptance of sNDA for Uzedy

Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks

Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation

Femasys announces publication of ‘positive’ results from FemBloc trials

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results From Fembloc® Permanent Birth Control Clinical Trials

THOMSON REUTERS

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Teva Pharmaceutical US Affiliate, Alvotech Selarsdi Injection Now Available in US

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4584/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1203.901,"timestamp":1741277559330,"preClose":1224.9326,"halted":0,"volume":3848054,"delay":0,"changeRate":-0.01717,"change":-21.031616,"pbRate":3.630796,"amount":48008736.756233,"amplitude":0.013636,"prevYearClose":1682.2216,"fiveDayClose":1255.7622,"twentyDayClose":1324.9594,"turnoverRate":0.002344,"marketCap":19613727322,"floatMarketCap":19483495036,"peRate":-10.849526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1211.8225,"amplitude":0.013636,"preClose":1224.9326,"low":1195.119,"pbRate":"3.630796","latestPrice":1203.901,"volume":3848052,"delay":0,"open":1200.6592,"prevYearClose":1682.2216,"prevWeekClose":1268.0868,"prevMonthClose":1268.0868,"prevQuarterClose":1682.2216,"fiveDayClose":1255.7622,"twentyDayClose":1324.9594,"sixtyDayClose":1391.0059,"secType":"PLATE","market":"US","turnoverRate":0.002344,"peRate":-10.849526,"marketCap":19613727322,"floatMarketCap":19483495036,"timestamp":1741277558025,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":4,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514867071","title":"MannKind Q4 Net Income USD 7.422 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867071?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX2FCC21:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2514867010","title":"MannKind Q4 Basic EPS USD 0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867010?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX2FCC21:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2514050867","title":"MannKind Q4 Pretax Profit USD 8.445 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514050867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514050867?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX2FCC21:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2514476350","title":"Teva, Medincell announce FDA acceptance of sNDA for Uzedy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514476350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514476350?lang=en_us&edition=fundamental","pubTime":"2025-02-26 06:05","pubTimestamp":1740521112,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug Application...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-medincell-announce-fda-acceptance-of-snda-for-uzedy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-medincell-announce-fda-acceptance-of-snda-for-uzedy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4557","TEVA","BK4566","BK4585","BK4584","BK4596","BK4588","BK4559","MDCLF"],"gpt_icon":0},{"id":"2514436630","title":"Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2514436630","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514436630?lang=en_us&edition=fundamental","pubTime":"2025-02-26 03:06","pubTimestamp":1740510413,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital.In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited  stands against the other stocks.In recognition of his accomplishments in wealth management, Morgan Stanley announced in 2022 that Zaro, then serving as a First Vice President and Financial Advisor at the firm’s Wealth Management office, was named to Forbes Magazine’s prestigious list of Top Next-Gen Wealth Advisors. This ranking evaluates candidates based on various qualitative and quantitative factors, including industry experience, leadership experience, assets under management, revenue trends, and compliance records. The selection process also inco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teva-pharmaceutical-industries-limited-teva-190653813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0320765646.SGD","LU0971096721.USD","LU1720051108.HKD","BK4557","IE00BZ1G4Q59.USD","LU2028103732.USD","LU1732800096.USD","LU2133065610.SGD","BK4516","BK4585","LU2271345857.HKD","LU0106261372.USD","BK4584","BK4559","IE00BKVL7J92.USD","LU0267386448.USD","LU2111349929.HKD","LU0106831901.USD","LU1989772923.USD","BK4127","LU0225283273.USD","LU1162221912.USD","BK4596","LU2357305700.SGD","BK4504","LU0006306889.USD","LU1720051017.SGD","BK4581","LU1548497426.USD","LU2023251221.USD","LU1989772840.SGD","TEVA","BK4566","LU0158827781.USD","BK4534","LU0098860793.USD","LU1074936037.SGD","LU0795875169.SGD","LU0158827948.USD","LU1363072403.SGD","LU0912757837.SGD","CFA","LU1732799900.SGD","LU2089284900.SGD","LU2347655156.SGD","LU0795875086.SGD","LU2089283258.USD","LU1668664300.SGD","BK4588"],"gpt_icon":0},{"id":"2514201262","title":"Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2514201262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514201262?lang=en_us&edition=fundamental","pubTime":"2025-02-26 01:15","pubTimestamp":1740503727,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Femasys (FEMY – Research Report), retaining the price target of $12.00. Emily Bo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/femasyss-fembloc-a-promising-investment-in-permanent-contraceptive-innovation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/femasyss-fembloc-a-promising-investment-in-permanent-contraceptive-innovation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","FEMY","BK4584","BK4082"],"gpt_icon":0},{"id":"2514523097","title":"Femasys announces publication of ‘positive’ results from FemBloc trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2514523097","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514523097?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:25","pubTimestamp":1740493510,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announces the peer-reviewed publication of “positive data” from its initial clinical trials of FemBloc permanent birth control in th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-publication-of-positive-results-from-fembloc-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-publication-of-positive-results-from-fembloc-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","FEMY","BK4584","BK4082"],"gpt_icon":0},{"id":"2514092710","title":"Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results From Fembloc® Permanent Birth Control Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2514092710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514092710?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:20","pubTimestamp":1740493200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA2HDNZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4082","FEMY","BK4539"],"gpt_icon":0},{"id":"2514862097","title":"Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862097","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514862097?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:20","pubTimestamp":1740493200,"startTime":"0","endTime":"0","summary":"--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners--. ATLANTA, Feb. 25, 2025  -- Femasys Inc., , a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the peer-reviewed publication of positive data from its initial clinical trials of FemBloc permanent birth control in the Journal of Gynecology & Reproductive Medicine , a leading peer-reviewed journal covering gynecology and reproductive medicine.“This peer-reviewed publication detailing positive prospective, multi-center clinical trial data for FemBloc brings Femasys closer to achieving our goal of providing a safer, more accessible in-office alternative to longstanding surgical sterilization for permanent contraception, without compromising effectiveness,” stated Kathy Lee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/femasys-announces-peer-reviewed-publication-142000250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","BK4539","FEMY","BK4584"],"gpt_icon":0},{"id":"2514777544","title":"Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514777544","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514777544?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:16","pubTimestamp":1740406575,"startTime":"0","endTime":"0","summary":"Wall Street analysts expect MannKind  to post quarterly earnings of $0.03 per share in its upcoming report, which indicates a year-over-year increase of 50%. Revenues are expected to be $75.66 million, up 29.4% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' foreca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unveiling-mannkind-mnkd-q4-outlook-141615558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNKD","BK4139","BK4584"],"gpt_icon":0},{"id":"2513721338","title":"Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2513721338","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513721338?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:22","pubTimestamp":1740403320,"startTime":"0","endTime":"0","summary":"On Saturday, Teva Pharmaceuticals Industries Ltd.  and Sanofi SA  presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug  for moderate-to-severe ulcerative colitis  and Crohn’s disease , the two most common forms of inflammatory bowel disease .These results were shared at the Congress of the European Crohn’s and Colitis Organisation.Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ‘Top Pick For 2025’。In the UC cohort of the RELIEVE UCCD study, 36%  and 48%  of patients treated with duvakitug achieved the primary endpoint of clinical remission  at week 14 compared to 20% treated with placebo.Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy -experienced and AT-nave subgroups of patients.AT-experienced: 29%  and 36% , with placebo-adjusted rates of 22%  and 29% .AT-nave: 39%  and 53% , with placebo-adjusted rates of 12%  a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-teva-unveil-detailed-data-132200188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CD","BK4585","BK4116","IBD","BK4566","SNY","SNYNF","BK4588","IE00BFXG1179.USD","BK4584","TEVA","BK4557","BK4559","BK4007","BK4596"],"gpt_icon":0},{"id":"2513936740","title":"Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2513936740","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513936740?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:59","pubTimestamp":1740398340,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb. 24, 2025  -- Generation Bio Co. , a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.Generation Bio is a biotechnology company changing what's possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell-selective cell-targeted lipid nanoparticle  to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. By selectively modulating T cells that drive disease pathology, ctLNP-siRNA therapeutics could potently block target function with sequence-level specificity while sparing the broader immune system. This potent new modality is designed to reach targets that a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/generation-bio-present-td-cowen-115900322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","GBIO","BK4585","BK4139","BK4127","TD","BK4566","COWN","BK4584"],"gpt_icon":0},{"id":"2513589407","title":"Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2513589407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513589407?lang=en_us&edition=fundamental","pubTime":"2025-02-23 21:40","pubTimestamp":1740318033,"startTime":"0","endTime":"0","summary":"Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 mon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-sanofi-present-new-results-from-relieve-uccd-phase-2b-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-sanofi-present-new-results-from-relieve-uccd-phase-2b-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4007","BK4588","BK4585","BK4596","IE00BFXG1179.USD","BK4559","SNYNF","TEVA","SNY","BK4557","BK4566"],"gpt_icon":0},{"id":"2513329260","title":"Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513329260","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513329260?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:15","pubTimestamp":1740143700,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., February 21, 2025----Aditxt, Inc.  , a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. , has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering . The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic Technology platform for early cancer detection and diagnosis.Pearsanta is developing a non-invasive blood-based test designed to detect cancer at earlier stages when treatment outcomes are more favorable. The Company’s proprietary Mitomic Technology leverages mitochondrial DNA deletions as biomarkers for disease detection, providing a unique approach to identifying malignancies. We believe that Pearsanta’s biomarker portfolio covers many high-clinical need cancers, with potential applications outside oncology.Pearsanta con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-pearsanta-engages-dominari-131500100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPO","BK4139","ADTX","EVFM","BK4007","BK4584"],"gpt_icon":0},{"id":"2513269747","title":"Teva Pharmaceutical US Affiliate, Alvotech Selarsdi Injection Now Available in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2513269747","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513269747?lang=en_us&edition=fundamental","pubTime":"2025-02-21 19:49","pubTimestamp":1740138562,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  US affiliate and Alvotech  said Friday that the Selarsdi injection is now available in the US to treat psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.Selarsdi is biosimilar to Stelara and it is the second biosimilar now available in the country under the Teva and Alvotech collaboration, they added.The US Food and Drug Administration provisionally determined that Selarsdi is interchangeable with the reference biologic Stelara after the first interchangeable biosimilar expires, on April 30, the parties said.Teva Pharmaceutical's stock rose 2.7%, while Alvotech's shares were up 3% in recent Friday premarket activity.Price: 17.46, Change: +0.46, Percent Change: +2.71","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALVO","BK4588","BK4566","BK4559","BK4584","BK4585","BK4596","TEVA","BK4007","BK4557"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":2,"totalSize":31}]}}